• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[血小板生成素受体激动剂用于慢性特发性血小板减少性紫癜急性加重期及随后下肢伴发深静脉血栓形成的抗凝治疗]

[Thrombopoietin receptor agonists administration for acute exacerbation of chronic idiopathic thrombocytopenic purpura and subsequent anticoagulant therapy for accompanying deep venous thrombosis of the lower limbs].

作者信息

Kawano Hiroki, Suzuki Tomohide, Ishii Shinichi, Wakahashi Kanako, Kawano Yuko, Sada Akiko, Minagawa Kentaro, Takaya Tomofumi, Yamashita Tomoya, Hirata Ken-Ichi, Koriyama Kenji, Nagamatsu Yuichi, Matsui Toshimitsu, Katayama Yoshio

机构信息

Department of Hematology, Kobe University Graduate School of Medicine.

出版信息

Rinsho Ketsueki. 2014 Jun;55(6):697-702.

PMID:24975340
Abstract

We report two patients (70- and 49-year-old Japanese men) with acute exacerbation of chronic idiopathic thrombocytopenic purpura (ITP) and deep venous thrombosis of the lower extremities. Both were successfully managed with thrombopoietin receptor agonist (TPO-RA) administration. Both had ITP refractory to steroid treatment. Their immature platelet fraction (absolute-IPF) counts were increased and paralleled the platelet recoveries after TPO-RA (eltrombopag and romiplostim, respectively) without progression of thrombosis. Although ITP has recently been evaluated as a thrombophilic disorder, reports on acute exacerbation of ITP with newly diagnosed thrombosis are limited, and the pathophysiology and association between ITP and thrombosis remain to be elucidated. Moreover, the influences of TPO-RA on thrombosis are still controversial. To our knowledge, this is the first case report describing patients with exacerbation of ITP who developed thrombosis and were treated with TPO-RA. The outcomes of our cases underscore the importance of monitoring thrombosis and not delaying the initiation of anticoagulation treatment during the use of TPO-RA.

摘要

我们报告了两名患有慢性特发性血小板减少性紫癜(ITP)急性加重并伴有下肢深静脉血栓形成的患者(分别为70岁和49岁的日本男性)。两者均通过给予血小板生成素受体激动剂(TPO-RA)成功治疗。两人的ITP对类固醇治疗均无效。他们的未成熟血小板分数(绝对未成熟血小板分数)计数增加,并且与TPO-RA(分别为艾曲泊帕和罗米司亭)治疗后的血小板恢复情况平行,且血栓形成未进展。尽管最近ITP被评估为一种易栓症,但关于新诊断血栓形成的ITP急性加重的报道有限,ITP与血栓形成之间的病理生理学及关联仍有待阐明。此外,TPO-RA对血栓形成的影响仍存在争议。据我们所知,这是首例描述ITP加重并发血栓形成并接受TPO-RA治疗患者的病例报告。我们病例的结果强调了在使用TPO-RA期间监测血栓形成以及不延迟启动抗凝治疗的重要性。

相似文献

1
[Thrombopoietin receptor agonists administration for acute exacerbation of chronic idiopathic thrombocytopenic purpura and subsequent anticoagulant therapy for accompanying deep venous thrombosis of the lower limbs].[血小板生成素受体激动剂用于慢性特发性血小板减少性紫癜急性加重期及随后下肢伴发深静脉血栓形成的抗凝治疗]
Rinsho Ketsueki. 2014 Jun;55(6):697-702.
2
Risk of thrombosis with thrombopoietin receptor agonists for ITP patients: A systematic review and meta-analysis.ITP 患者使用血小板生成素受体激动剂的血栓形成风险:系统评价和荟萃分析。
Crit Rev Oncol Hematol. 2022 Mar;171:103581. doi: 10.1016/j.critrevonc.2022.103581. Epub 2022 Jan 7.
3
Portal vein thrombosis as complication of romiplostim treatment in a cirrhotic patient with hepatitis C-associated immune thrombocytopenic purpura.门静脉血栓形成是 romiplostim 治疗丙型肝炎相关免疫性血小板减少性紫癜合并肝硬化患者的并发症。
J Hepatol. 2011 Jul;55(1):229-32. doi: 10.1016/j.jhep.2011.01.020. Epub 2011 Mar 23.
4
Sustained remission of chronic immune thrombocytopenia after discontinuation of treatment with thrombopoietin-receptor agonists in adults.成人停用血小板生成素受体激动剂治疗后慢性免疫性血小板减少症的持续缓解
Int J Hematol. 2015 Jul;102(1):7-11. doi: 10.1007/s12185-015-1793-1. Epub 2015 Apr 2.
5
Effect of thrombopoietin receptor agonists on leukocyte and haematopoietic stem and progenitor cells in the peripheral blood of patients with immune thrombocytopenic purpura.血小板生成素受体激动剂对免疫性血小板减少性紫癜患者外周血白细胞及造血干细胞和祖细胞的影响。
Ann Hematol. 2017 Dec;96(12):2045-2056. doi: 10.1007/s00277-017-3131-6. Epub 2017 Sep 30.
6
Thrombopoietin receptor agonist (TPO-RA) treatment raises platelet counts and reduces anti-platelet antibody levels in mice with immune thrombocytopenia (ITP).促血小板生成素受体激动剂(TPO-RA)治疗可提高免疫性血小板减少症(ITP)小鼠的血小板计数并降低抗血小板抗体水平。
Platelets. 2020;31(3):399-402. doi: 10.1080/09537104.2019.1624709. Epub 2019 May 30.
7
Efficacy and safety of thrombopoietin receptor agonists in children with chronic immune thrombocytopenic purpura: meta-analysis.促血小板生成素受体激动剂治疗儿童慢性免疫性血小板减少性紫癜的疗效和安全性:Meta 分析。
Platelets. 2019;30(7):828-835. doi: 10.1080/09537104.2019.1572873. Epub 2019 Feb 27.
8
Is ITP a thrombophilic disorder?ITP 是否为血栓形成倾向疾病?
Am J Hematol. 2016 Jan;91(1):39-45. doi: 10.1002/ajh.24234. Epub 2015 Nov 26.
9
A case of acute stent thrombosis during treatment with the thrombopoietin receptor agonist peptide--romiplostim.一例在使用血小板生成素受体激动剂肽--罗米司亭治疗期间发生的急性支架血栓形成。
Heart Lung Circ. 2012 Mar;21(3):182-4. doi: 10.1016/j.hlc.2011.09.001. Epub 2011 Oct 2.
10
Cytokine changes in response to TPO receptor agonist treatment in primary immune thrombocytopenia.原发性免疫性血小板减少症中细胞因子对血小板生成素受体激动剂治疗的反应变化
Cytokine. 2017 Apr;92:110-117. doi: 10.1016/j.cyto.2017.01.013. Epub 2017 Jan 29.